Variations in pre-hospital fibrinolysis process of care: Insights from the assessment of the safety and efficacy of a new thrombolytic 3 plus international acute myocardial infarction pre-hospital care survey

European Journal of Emergency Medicine

Volumn 11, Issue 3, 2004, Pages 134-140

  Welsh, Robert C ^a   Goldstein, Patrick ^b   Adgey, Jennifer ^c   Verheugt, Freek ^d   Bestilny, Shirley A ^a   Wallentin, Lars ^e   Werf, Frans Van de ^f   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Clinical practice variation; Myocardial infarction; Pre hospital emergency care; Thrombolysis

Indexed keywords

ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EMERGENCY HEALTH SERVICE; EPIDEMIOLOGY; EUROPE; FIBRINOLYTIC THERAPY; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; UNITED STATES;

CANADA; EMERGENCY MEDICAL SERVICES; ENOXAPARIN; EUROPE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 4644294539     PISSN: 09699546     EISSN: 14735695     Source Type: Journal    
DOI: 10.1097/01.mej.0000127653.61705.54     Document Type: Article

References (17)

1. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771-775.
2. Yuling F, Goodman S, Chang W-C, Van de Werf F, Granger CB, Armstrong PW, for the ASSENT 2 Trail Investigators. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation 2001; 104:2653-2659.
3. Lamfers EJP, Hooghoudt THE, Uppelschoten A, Stolwijk PWJ, Verheugt FWA. Effect of prehospital thrombolysis on aborting acute myocardial infarction. Am J Cardiol 1999; 84:928-930, A6-A7.
4. Armstrong P, Fu Y, Goodman S, Van de Werf F, Granger CB. The nature and outcome of patients who avoid myocardial necrosis after fibrinolysis [Abstract]. Eur Heart J 2001; 22 (Suppl.):179.
5. Raitt MH, Maynard C, Wagner GS, Cerqueira MD, Selvester RH, Weaver WD. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Circulation 1996; 93:48-53.
6. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. et al. Pre-hospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211-1216.
7. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941-2947.
8. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999; 100:14-20.
9. Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. Am Heart J 2003; 145:1-8.
10. The ASSENT-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605-613.
11. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and pre-hospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283:2686-2692.
12. Morrow DA, Antman EM, Sayah A, Schulwerk KC, Giugliano RP, deLemos JA, et al. Evaluation of the time saved by pre-hospital initiation of reteplase for ST-elevation myocardial infarction. Results of the early retavase-thrombolysis in myocardial infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002; 40:71-77.
13. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low molecular weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 Plus randomized trial in acute myocardial infarction. Circulation 2003; 108:135-142.
14. Gibler WB, Topol EJ, Holroyd B, Armstrong PW. Cardiology and emergency medicine: united we stand, divided we fall. Ann Emerg Med 2002; 39:164-167.
15. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361:13-20.
16. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al., on behalf of the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002; 360:825-829.
17. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al., on behalf of the ‘PRAGUE’ Study Group Investigators. Long distance transport for primary angioplasty vs. immediate thrombolysis in acute myocardial infarction. Eur Heart J 2003; 24:94-104.